Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins

• Authors: Sharad Purohit, Augusta University; Tiehai Li, Georgia State University; Wanyi Guan, Georgia State University; Xuezheng Song, Emory University; Jing Song, Georgia State University; Yanna Tian, Augusta University; Lei Li, Georgia State University; Ashok Sharma, Augusta University; Boying Dun, Augusta University; David Mysona, Augusta University; Sharad Ghamande, Augusta University; Bunja Rungruang, Augusta University; Richard D. Cummings, Harvard Medical School; Peng George Wang, Georgia State University; Jin-Xiong She, Augusta University
• Journal Title: Nature Communications
• Volume: Volume 9, Number 1
• Publisher: Nature Publishing Group | 2018-01-17, Pages 258-258
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1038/s41467-017-02747-y
• Subjects: Health Sciences, Obstetrics and Gynecology; Chemistry, Biochemistry
• Keywords: Science & Technology; Multidisciplinary Sciences; Science & Technology - Other Topics; INFLAMMATORY-BOWEL-DISEASE; MICROARRAY STRATEGY; SEROLOGIC MARKERS; SERUM ANTIBODIES; OVARIAN-CANCER; PROSTVAC-VF; GLYCOSYLATION; IMMUNOASSAY; DIAGNOSIS; REVEALS

Abstract

Glycan-binding proteins (GBPs) play critical roles in diverse cellular functions such as cell adhesion, signal transduction and immune response. Studies of the interaction between GBPs and glycans have been hampered by the availability of high throughput and high-content technologies. Here we report multiplex glycan bead array (MGBA) that allows simultaneous analyses of 384 samples and up to 500 glycans in a single assay. The specificity, sensitivity and reproducibility of MGBA are evaluated using 39 plant lectins, 13 recombinant anti-glycan antibodies, and mammalian GBPs. We demonstrate the utility of this platform by the analyses of natural anti-glycan IgM and IgG antibodies in 961 human serum samples and the discovery of anti-glycan antibody biomarkers for ovarian cancer. Our data indicate that the MGBA platform is particularly suited for large population-based studies that require the analyses of large numbers of samples and glycans.